Search Clinical Trials
585,889 trials
ID
Status
Phase
Title
Sponsor
NCT07602933
Photobiomodulation Effects on Fatigue and Muscle Damage Induced by NMESConselho Nacional de Desenvolvimento Científico e TecnológicoNot Yet RecruitingNot Applicable
NCT07602933Not Yet Recruiting
Not Applicable
Photobiomodulation Effects on Fatigue and Muscle Damage Induced by NMESConselho Nacional de Dese...
NCT07605091
RELIANCE: Moringa in Lactation and Early ChildhoodPhilip KernNot Yet RecruitingNot Applicable
NCT07605091Not Yet Recruiting
Not Applicable
RELIANCE: Moringa in Lactation and Early ChildhoodPhilip Kern
NCT07600853
Development and Validation of an E-learning Module on Systemic Anticancer Therapy and Its Effectiveness on the Knowledge Attitude and Practice of Nurses in Administering Systemic Anticancer Agents at a Specialized Cancer Centres in Oman.Sultan Qaboos Comprehensive Cancer CenterNot Yet RecruitingNot Applicable
NCT07600853Not Yet Recruiting
Not Applicable
Development and Validation of an E-learning Module on Systemic Anticancer Therap...Sultan Qaboos Comprehensi...
NCT07603765
Minimally Invasive Hemodynamic Monitoring in Cardiac AblationIstanbul University - CerrahpasaRecruiting
NCT07603765Recruiting
—
Minimally Invasive Hemodynamic Monitoring in Cardiac AblationIstanbul University - Cer...
NCT07600775
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)Merck Sharp & Dohme LLCNot Yet RecruitingPhase 1
NCT07600775Not Yet Recruiting
Phase 1
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuber...Merck Sharp & Dohme LLC
NCT07604909
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant ChemotherapyFudan UniversityRecruitingPhase 2
NCT07604909Recruiting
Phase 2
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Thera...Fudan University
NCT07601009
Validity and Reliability of a Mixed Reality-Based 6-Minute Walk TestSelcuk UniversityRecruiting
NCT07601009Recruiting
—
Validity and Reliability of a Mixed Reality-Based 6-Minute Walk TestSelcuk University
NCT07601737
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaShanghai General Hospital, Shanghai Jiao Tong University School of MedicineRecruitingPhase 2
NCT07601737Recruiting
Phase 2
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of L...Shanghai General Hospital...
NCT07600866
Validation of a Body-Composition Segmentation Software on a Diverse Public CT Scan CohortNucleo Research, Inc.Not Yet Recruiting
NCT07600866Not Yet Recruiting
—
Validation of a Body-Composition Segmentation Software on a Diverse Public CT Sc...Nucleo Research, Inc.
NCT07603050
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's DiseaseShanghai Vitalgen BioPharma Co., Ltd.Not Yet RecruitingPhase 1
NCT07603050Not Yet Recruiting
Phase 1
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in P...Shanghai Vitalgen BioPhar...
NCT07602530
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical PracticeAstellas Pharma Europe Ltd.Recruiting
NCT07602530Recruiting
—
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezoline...Astellas Pharma Europe Lt...
NCT07604363
High-Fidelity Simulation and Longitudinal Outcomes in Novice Nurses (HFS-NOVA)Tri-Service General HospitalCompletedNot Applicable
NCT07604363Completed
Not Applicable
High-Fidelity Simulation and Longitudinal Outcomes in Novice Nurses (HFS-NOVA)Tri-Service General Hospi...
NCT07601282
Development and Validation of a Risk Prediction Model for De Novo Stress Urinary Incontinence After Pelvic Floor Reconstruction SurgeryShanghai General Hospital, Shanghai Jiao Tong University School of MedicineRecruiting
NCT07601282Recruiting
—
Development and Validation of a Risk Prediction Model for De Novo Stress Urinary...Shanghai General Hospital...
NCT07602699
Multi-Site Trial of Tirzepatide for Smoking CessationNational Institute on Drug Abuse (NIDA)RecruitingPhase 2
NCT07602699Recruiting
Phase 2
Multi-Site Trial of Tirzepatide for Smoking CessationNational Institute on Dru...
NCT07604142
Allogenic Bone Block for Oro-Antral Communication Closure for Subsequent Implant PlacementTanta UniversityEnrolling By InvitationNot Applicable
NCT07604142Enrolling By Invitation
Not Applicable
Allogenic Bone Block for Oro-Antral Communication Closure for Subsequent Implant...Tanta University
NCT07604025
Senna vs. Polyethylene Glycol 3350 for the Treatment of Retentive Encopresis in Children: a Randomized, Double-blinded, StudyAssaf-Harofeh Medical CenterNot Yet RecruitingEarly Phase 1
NCT07604025Not Yet Recruiting
Early Phase 1
Senna vs. Polyethylene Glycol 3350 for the Treatment of Retentive Encopresis in...Assaf-Harofeh Medical Cen...
NCT07603856
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerUniversity of ChicagoNot Yet RecruitingPhase 2
NCT07603856Not Yet Recruiting
Phase 2
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Sma...University of Chicago
NCT07602010
Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer StagingOslo University HospitalRecruiting
NCT07602010Recruiting
—
Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer StagingOslo University Hospital
NCT07600788
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.Ausper Biopharma Co., Ltd.Not Yet RecruitingPhase 1
NCT07600788Not Yet Recruiting
Phase 1
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AH...Ausper Biopharma Co., Ltd...
Result Breakdown
Not yet recruiting10 (50%)
Recruiting8 (40%)
Completed1 (5%)
Enrolling by invitation1 (5%)
not_applicable6 (30%)
Not Specified6 (30%)
Phase 24 (20%)
Phase 13 (15%)
Early Phase 11 (5%)